PTAB Negates Novartis Patent on MS Treatment Gilenya

Generic Line
The Patent Trial and Appeal Board has invalidated a patent for Novartis’ multiple sclerosis drug Gilenya, in one of the first successful uses of the inter partes review process by generics drugmakers.

To View This Article:


Subscribe To Generic Line

Buy This Article Now

Add this article to your cart for $40.00